SOURCE: OraPharma, Inc.

June 01, 2005 09:00 ET

76% of Dental Professionals Surveyed by Health Products Research, Inc.® Say OraPharma Provides the Best Level of Customer Support

Manufacturer of ARESTIN® Provides Best Support Among Oral Health Companies Involved in Periodontal Disease Treatment and Management

WARMINSTER, PA -- (MARKET WIRE) -- June 1, 2005 -- OraPharma, Inc., a pharmaceutical company specializing in products for the dental market, was rated as the top company for customer support by a survey of dental health professionals recently conducted by Health Products Research, Inc.® (HPR).

According to James Charnetski, Vice President of Market Research/Health Products Research, "The fact that over three-quarters of the dental offices surveyed cited OraPharma as providing the best level of support to their practice out of companies with an interest in the management of periodontal disease clearly places the organization as the best in its class. A score of 50% is considered a significant accomplishment -- the 76% level demonstrates OraPharma's commitment to providing unsurpassed service and support for its customers."

The extensive blinded research findings were the result of HPR's Metropolitan Area Promotional Audit (MPA). This self-reported diary was completed by 647 randomly selected offices from across the U.S. Offices were queried on their hygiene and periodontal disease treatment protocols as well as the products they use and the companies that support those products.

"We are very proud of the HPR survey result," said Michael Cavanaugh, Executive Director, Marketing. "Our commercial team received very high ratings from dental practitioners, especially pertaining to our account managers' professionalism and our innovative support of dental professionals and their patients."

About OraPharma, Inc.

OraPharma, Inc., a Johnson & Johnson company, is a specialty pharmaceutical company, which discovers, develops, and commercializes therapeutics for oral health. OraPharma is dedicated to the dental community, specifically the periodontal space, with its lead product, ARESTIN®, indicated as an adjunct to scaling and/or root planing procedures for adult patients with periodontitis.

In addition to ARESTIN®, OraPharma also distributes Oraqix® (lidocaine and prilocaine periodontal gel) 2.5% / 2.5%, a new sub-gingival local anesthetic periodontal gel, indicated for adults who require localized anesthesia in periodontal pockets during scaling and/or root planing and is manufactured by Dentsply Pharmaceuticals.

Along with ARESTIN and Oraqix, OraPharma also promotes Johnson & Johnson's REACH Access and Act x2 to the dental community.

About ARESTIN®

OraPharma's flagship product ARESTIN is indicated as an adjunct to scaling and/or root planing procedures for reduction of pocket depth in patients with adult periodontitis. ARESTIN may be used as part of a periodontal maintenance program which includes good oral hygiene and scaling and/or root planing. For detailed product information, visit www.arestin.com.

About Oraqix®

Oraqix®, manufactured for OraPharma, Inc. by Dentsply Pharmaceuticals, is the first FDA-approved subgingival anesthetic indicated for use in adults requiring anesthesia for SRP procedures. The patient friendly, needle-free application avoids patients concerns about needles and injections.

For more information, visit www.orapharma.com or call 1-866-273-7846.

(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the Company's expectations and projections. Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99(b) of the Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 2004. Copies of this Form 10-K are available online at www.sec.gov or on request from the Company. The Company assumes no obligation to update any forward-looking statements as a result of new information or future events or developments.) For more information on Johnson & Johnson, please visit the Company's website at www.jnj.com.

Contact Information